Cim LLC Grows Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Cim LLC raised its holdings in DexCom, Inc. (NASDAQ:DXCM) by 4.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,578 shares of the medical device company’s stock after purchasing an additional 432 shares during the quarter. Cim LLC’s holdings in DexCom were worth $1,199,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in DXCM. Vanguard Group Inc. grew its position in DexCom by 0.3% during the first quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock valued at $6,186,539,000 after buying an additional 136,282 shares during the period. Capital Research Global Investors raised its holdings in DexCom by 21.4% in the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after purchasing an additional 2,695,296 shares during the period. Capital World Investors boosted its position in DexCom by 130.7% during the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after purchasing an additional 5,256,092 shares in the last quarter. Blair William & Co. IL grew its holdings in DexCom by 1.4% in the first quarter. Blair William & Co. IL now owns 4,532,687 shares of the medical device company’s stock valued at $628,684,000 after purchasing an additional 64,683 shares during the period. Finally, Legal & General Group Plc increased its position in shares of DexCom by 1.7% in the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock valued at $339,352,000 after buying an additional 49,076 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. JPMorgan Chase & Co. lowered shares of DexCom from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $145.00 to $75.00 in a research report on Friday, July 26th. Stifel Nicolaus lifted their price target on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Oppenheimer cut their price objective on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, July 26th. StockNews.com upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Tuesday, September 24th. Finally, BTIG Research cut their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Six analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $112.25.

Insider Transactions at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other DexCom news, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the sale, the executive vice president now directly owns 66,249 shares in the company, valued at $4,607,617.95. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. The disclosure for this sale can be found here. Insiders have sold 1,824 shares of company stock worth $126,390 over the last quarter. 0.30% of the stock is currently owned by insiders.

DexCom Stock Performance

NASDAQ:DXCM opened at $66.00 on Wednesday. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a market capitalization of $26.25 billion, a P/E ratio of 42.58, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The firm has a 50-day moving average price of $71.85 and a two-hundred day moving average price of $106.17.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.34 earnings per share. As a group, research analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.